Aethlon Medical Inc
$ 3.15
4.30%
07 Aug - close price
- Market Cap 1,659,100 USD
- Current Price $ 3.15
- High / Low $ 3.27 / 3.00
- Stock P/E N/A
- Book Value 15.56
- EPS -53.05
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.67 %
- ROE -1.43 %
- 52 Week High 27.40
- 52 Week Low 0.53
About
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$16.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-06-10 | 2026-02-12 | 2025-11-12 | 2025-08-13 | 2025-06-26 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-06-27 | 2024-02-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -1.1998 | -2.45 | -3.74 | -8.5 | -3.44 | -10.4 | -16 | -27.2 | -0.91 | -109.6 | -97.6 | -112 |
| Estimated EPS | -2.45 | -2.01 | -3.66 | -7.3 | -1.11 | -16.27 | -15.6 | -25.2 | -1.25 | -109.33 | -112 | -104 |
| Surprise | 1.2502 | -0.44 | -0.08 | -1.2 | -2.33 | 5.87 | -0.4 | -2 | 0.34 | -0.27 | 14.4 | -8 |
| Surprise Percentage | 51.0286% | -21.8905% | -2.1858% | -16.4384% | -209.9099% | 36.0787% | -2.5641% | -7.9365% | 27.2% | -0.247% | 12.8571% | -7.6923% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AEMD
2026-08-08 12:39:40
Aethlon Medical (AEMD.US) is scheduled to release its earnings report after the market closes on August 13. Investors and analysts will be watching closely for the company's financial performance.
2026-08-07 07:41:29
This article provides comprehensive financial data for Aethlon Medical, Inc. (AEMD), including its current stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on developing immunotherapeutic devices like the Hemopurifier and compares its performance against the S&P 500. The company's stock closed at $3.02 with a 7.08% decrease, and its 1-year target estimate is $16.25.
2026-08-07 07:41:29
This Yahoo Finance page provides a comprehensive overview of Aethlon Medical, Inc. (AEMD) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's focus on developing immunotherapeutic devices and offers comparisons with similar medical device companies. Key financial metrics, recent news, and performance against benchmarks like the S&P 500 are also presented.
2026-08-06 12:39:40
Aethlon Medical (Nasdaq:AEMD) is a medical therapeutic company developing novel immunotherapeutic devices, particularly the Hemopurifier, for oncology, infectious diseases, and organ transplantation. The company is currently engaged in clinical trials in Australia for its Hemopurifier in cancer patients, showing promising directional biological changes in early cohorts. Despite these developments, Aethlon Medical faces significant financial risks including negative earnings forecasts, shareholder dilution, low revenue, and a volatile share price, leading to a low market capitalization.
2026-08-06 11:40:30
This article focuses on the Capital Expenditure (CapEx) per share for Aethlon Medical, Inc. (FWB:EJU) as listed on TradingView. It appears to be a financial data page rather than an analytical article, showing "No trades" and providing general information about the company's financials, documents, news, and community.
2026-08-06 11:09:13
This page provides a comprehensive overview of Aethlon Medical, Inc. (AEMD) stock, including its current price, historical data, financial performance, and analyst insights. Aethlon Medical, Inc. is a medical therapeutic company that develops immunotherapeutic devices like the Hemopurifier for various diseases. The stock has shown significant declines over multiple periods and analysts have a target estimate of $16.25, with a neutral rating.
